Home » Topics » BioWorld Science, Dermatologic

BioWorld Science, Dermatologic
RSS

Almirall and Nuevolution to jointly develop RORgammat inhibitors

Dec. 13, 2016

Purdue Pharma and Exicure enter collaboration agreement in psoriasis

Dec. 13, 2016

Valeant Pharmaceuticals reports positive results from phase III study of IDP-118

Dec. 12, 2016

EMA accepts for review MAA for dupilumab in atopic dermatitis

Dec. 9, 2016

Dosing begins in phase III program of ReVance Therapeutics' daxibotulinumtoxinA

Dec. 9, 2016

Aclaris Therapeutics clear to begin phase I testing of ATI-50001

Dec. 9, 2016

AmorePacific initiates phase III trial of PAC-14028 in atopic dermatitis

Dec. 2, 2016

Novan reports topline results from phase II study of SB-206

Nov. 30, 2016

PRMT5 inhibitors could represent new therapeutic approach in treatment of psoriatic diseases

Nov. 29, 2016

Janssen-Cilag seeks approval of guselkumab in Europe

Nov. 25, 2016

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 10, 2026.
Hengrui discovers new Nav1.8 blockers
BioWorld Science
Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 7, 2026
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld
Hematopoietic stem cell research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
Korsana boosts Alzheimer’s work with reverse merger, $380M financing
BioWorld Science
Just over a month after emerging from stealth and disclosing a $150 million series A, Korsana Biosciences Inc. is making the leap to the public market via a...